UG

UNITED GUARDIAN INC - 10-Q Summary (Period Ended Sep 30, 2008)

Business Context and Reporting Period

United Guardian Inc. is a Delaware corporation engaged in the research, development, manufacturing, and marketing of cosmetic ingredients, personal care products, pharmaceuticals, and specialty industrial products. The company operates as a smaller reporting company. This filing covers the quarterly period ended September 30, 2008, and the nine-month period ended on the same date. The company's primary manufacturing facility is located in Hauppauge, New York.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Nine-month revenue increased 1.0% ($92,407) compared to 2007. However, the third quarter (three months) saw a significant 32.1% increase ($850,875) driven by higher sales volumes in personal care and pharmaceuticals.
• Profitability: Net income for the nine months decreased 7.1% to $2.49 million, primarily due to lower investment income and higher costs of sales. Conversely, third-quarter net income increased 16.4% to $911,494.
• Margins: Cost of sales as a percentage of sales increased to 43.9% for the nine months (from 40.0% in 2007) and 46.7% for the quarter (from 36.8%). This was attributed to rising raw material, energy, and transportation costs.
• Liquidity: Working capital increased to $14.1 million, and the current ratio improved to 13.0:1 from 6.7:1 at year-end 2007, largely due to the payment of dividends payable and an increase in accounts receivable.
• Investments: Investment income decreased 18.2% for the nine months due to lower interest rates and returns. The company held $7.2 million in marketable securities as of September 30, 2008, with an unrealized loss of $270,298.

Guidance, Outlook, and Risks

• Outlook: Management expects full-year pharmaceutical revenue to equal or exceed 2007 levels. The company believes its working capital is sufficient to support operations for the next twelve months.
• Dividends: The company paid dividends of $2.72 million during the nine-month period, an increase from the prior year due to a higher dividend per share ($0.28 vs $0.22 in Q1).
• Pension Plan: The company decided to terminate its defined benefit pension plan in February 2008, subject to regulatory approval expected in 2009. A new defined contribution plan has been accrued.
• Discontinued Operations: The company completed the sale of its Eastern Chemical Corporation subsidiary in December 2007. Remaining assets and liabilities were fully liquidated in Q2 2008.
• Risks: Key risks include concentration of credit risk (Customer A represented 59.2% of accounts receivable), reliance on major distributors, raw material cost escalation, and general economic conditions affecting international sales.
• Line of Credit: The company's $2 million line of credit with JP Morgan Chase expired in June 2008 and was not renewed as the company deemed the cost unjustified given its strong cash position.

Investor Verification Checklist

• Customer Concentration: Verify the stability of "Customer A," which accounted for 59.2% of accounts receivable and a significant portion of revenue.
• Cost Inflation: Monitor the trajectory of raw material and energy costs, which have compressed gross margins significantly in the third quarter.
• Investment Portfolio: Review the unrealized losses on marketable securities ($270k) and the impact of interest rate changes on investment income.
• Pension Termination: Track the regulatory approval status of the pension plan termination and potential one-time gains or losses upon finalization.
• Dividend Sustainability: Assess the long-term sustainability of dividend payouts given the reduction in operating cash flow compared to the prior year.